
Article 1 

1. The quantity of controlled substances of Group I (chlorofluorocarbons 11, 12, 113, 114 and 115) subject to Regulation (EC) No 2037/2000 which may be used for essential medical uses in the Community in 2006 shall be 539 000,0 ODP kilograms.
2. The quantity of controlled substances of Group I (chlorofluorocarbons 11, 12, 113, 114 and 115) and Group II (other fully halogenated chlorofluorocarbons) subject to Regulation (EC) No 2037/2000 which may be used for essential laboratory uses in the Community in 2006 shall be 256 761,86 ODP kilograms.
3. The quantity of controlled substances of Group III (halons) subject to Regulation (EC) No 2037/2000 that may be used for essential laboratory use in the Community in 2006 shall be 482,70 ODP kilograms.
4. The quantity of controlled substances of Group IV (carbon tetrachloride) subject to Regulation (EC) No 2037/2000 that may be used for essential laboratory uses in the Community in 2006 shall be 149 641,536 ODP kilograms.
5. The quantity of controlled substances of Group V (1,1,1-trichloroethane) subject to Regulation (EC) No 2037/2000 that may be used for essential laboratory uses in the European Union in 2006 shall be 754,00 ODP kilograms.
6. The quantity of controlled substances of Group VI (methyl bromide) subject to Regulation (EC) No 2037/2000 that may be used for laboratory and analytical uses in the Community in 2006 shall be 300,00 ODP kilograms.
7. The quantity of controlled substances of Group VII (hydrobromofluorocarbons) subject to Regulation (EC) No 2037/2000 that may be used for essential laboratory uses in the Community in 2006 shall be 4,49 ODP kilograms.
8. The quantity of controlled substances of group IX (bromochloromethane) subject to Regulation (EC) No 2037/2000 that may be used for essential laboratory uses in the Community in 2006 shall be 13,308 ODP kilograms.
Article 2 
The chlorofluorocarbon metered-dose inhalers listed in Annex I shall not be placed on markets where the Competent Authority has determined chlorofluorocarbonsfor metered-dose inhalers on those markets to be non-essential.
Article 3 
During the period 1 January to 31 December 2006 the following rules shall apply:

1.. The allocation of essential medical use quotas for chlorofluorocarbons 11, 12, 113, 114 and 115 shall be to the companies indicated in Annex II.
2.. The allocation of essential laboratory use quotas for chlorofluorocarbons 11, 12, 113, 114 and 115 and other fully halogenated chlorofluorocarbons shall be to the companies indicated in Annex III.
3.. The allocation of essential laboratory use quotas for halons shall be to the companies indicated in Annex IV.
4.. The allocation of essential laboratory use quotas for carbon tetrachloride shall be to the companies indicated in Annex V.
5.. The allocation of essential laboratory use quotas for 1,1,1-trichloroethane shall be to the companies indicated in Annex VI.
6.. The allocation of laboratory and analytical critical use quotas for methyl bromide shall be to the companies indicated in Annex VII.
7.. The allocation of essential laboratory use quotas for hydrobromofluorocarbons shall be to the companies indicated in Annex VIII.
8.. The allocation of essential laboratory use quotas for bromochloromethane shall be to the companies indicated in Annex IX.
9.. The essential use quotas for chlorofluorocarbons 11, 12, 113, 114 and 115, other fully halogenated chlorofluorocarbons, carbon tetrachloride, 1,1,1-trichloroethane, hydrobromofluorocarbons and bromochloromethane shall be as set out in Annex X.
Article 4 
This Decision shall apply from 1 January 2006 and shall expire on 31 December 2006.
Article 5 
This Decision is addressed to the following undertakings:

 3M Health Care Ltd3M House Morley StreetLoughboroughLeicestershire LE11 1EPUnited Kingdom
 Bespak PLCNorth Lynn Industrial EstateKing's LynnPE30 2JJ — NorfolkUnited Kingdom
 Boehringer Ingelheim GmbHBinger Straße 173D-55216 Ingelheim am Rhein
on behalf of Boehringer Ingelheim (France)
 Chiesi Farmaceutici SpAVia Palermo, 26/AI-43100 Parma
 IVAX LtdUnit 301 Industrial ParkWaterfordIreland
 Laboratorio Aldo Union SABaronesa de Maldá, 73Espluges de LlobregatE-08950 Barcelona
 SICOR SpAVia Terrazzano, 77I-20017 Rho (MI)
 Valeas SpA PharmaceuticalsVia Vallisneri, 10I-20133 Milano
 Valvole Aerosol Research Italiana (VARI)Spa — LINDAL Group ItaliaVia del Pino, 10I-23854 Olginate (LC)
 Acros Organics bvbaJanssen Pharmaceuticalaan 3oB-2440 Geel
 Airbus Franceroute de Bayonne 316F-31300 Toulouse
 Biosolove B.V.Waalreseweg 175554 HA ValkenswaardNederland
 Bie & BerntsenSandbækvej 7DK-2610 Roedovre
 Carlo Erba Reactifs-SDSZ.I. de Valdonne, BP 4F-13124 Peypin
 CNRS — Groupe de Physique des SolidesUniversité Paris, 7 Denis Diderot & Paris6 Pierre et Marie CurieF-75251 Paris Cedex 5
 Health Protection Inspectorate-LaboratoriesPaldiski mnt 81EE-10617 Tallinn
 Honeywell Fluorine Products EuropeKempenweg 90P.O. Box 2646000 AG WeertNederland
 Honeywell Specialty ChemicalsWunstorfer Straße 40Postfach 100262D-30918 Seelze
 Ineos Fluor LtdPO Box 13, The HeathRuncorn Cheshire WA7 4QFUnited Kingdom
 Institut Scientifique de Service Public (ISSeP)Rue du Chéra, 200B-4000 Liège
 Katholieke Universiteit LeuvenKrakenstraat 3B-3000 Leuven
 LGC Promochem GmbHMercatorstraße 51D-46485 Wesel
 Mallinckrodt Baker BVTeugseweg 207418 AM DeventerNederland
 Merck KgaAFrankfurter Straße 250D-64271 Darmstadt
 Mikro+Polo d.o.o.Lackova 78SLO-2000 Maribor
 Ministry of DefenseDirectorate Material RNL NavyPO Box 20702500 ES The HagueNederland
 Panreac Química SARiera de Sant Cugat 1E-08110 Montcada I Reixac (Barcelona)
 Sanolabor d.d.Leskovškova 4SLO-1000 Ljubljana
 Sigma Aldrich Logistik GmbHRiedstraße 2D-89555 Steinheim
 Sigma Aldrich Chimie SARL80, rue de LuzaisL'isle-d'abeau ChesnesF-38297 Saint-Quentin-Fallavier
 Sigma Aldrich Company LtdThe Old BrickyardNew Road Gillingham SP8 4XTUnited Kingdom
 Sigma Aldrich LaborchemikalienWunstorfer Straße 40Postfach 100262D-30918 Seelze
 Sigma Aldrich Chemie GmbHRiedstraße 2D-89555 Steinheim
 Tazzetti Fluids S.r.l.Corso Europa, 600/aI-10088 Volpiano (TO)
 University of Technology ViennaInstitut of Industrial Electronics&Material ScienceGusshausstraße 27-29A-1040 Wien
 VWR I.S.A.S.201, rue CarnotF-94126 Fontenay-sous-Bois
 YA-Kemia Oy — Sigma Aldrich FinlandTeerisuonkuja 4FI-00700 Helsinki
Done at Brussels, 11 April 2006.
For the Commission
Stavros DIMAS
Member of the Commission
ANNEX I
Pursuant to paragraph 3 of Decision XII/2 of the Twelfth Meeting of the Parties to the Montreal Protocol on measures to facilitate the transition to chlorofluorocarbon-free metered-dose inhalers (MDIs), the following countries have determined that, due to the presence of suitable non-CFC MDIs, CFCs no longer qualify as ‘essential’ under the Protocol when combined with following active ingredients:

Country Short-acting Beta Agonist Bronchodilators
Salbutamol Terbutaline Fenoterol Orciprenaline Reproterol Carbuterol Hexoprenaline Pirbuterol Clenbuterol Bitolterol Procaterol
Austria X X X X X X X X X X X
Belgium X X X X X X X X X X X
Cyprus X          
Czech Republic X X X X X X X X X X X
Denmark X  X X X X X X X X X
Estonia X X X X X X X X X X X
Finland X          
France X          
Germany X X X X X X X X X X X
Greece X X X X X X X X X X X
Hungary X X X X X X X X X X X
Ireland X          
Italy X          
Latvia X X X X X X X X X X X
Lithuania X X X X X X X X X X X
Luxembourg X          
Malta X          
Netherlands X X X X X X X X X X X
Poland X          
Portugal X X X X X X X X X X X
Norway X X X X X X X X X X X
Slovak Republic X X X X X X X X X X X
Slovenia X X X X X X X X X X X
Spain X          
Sweden X          
United Kingdom X          
Source: www.unep.org/ozone/Information_for_the_Parties/3Bi_dec12-2-3.asp
Country Inhaled steroids
Beclomethasone Dexamethasone Flunisolide Fluticasone Budesonide Triamcinolone
Austria      
Belgium X X X X X X
Cyprus      
Czech Republic X X X X X X
Denmark X   X  
Estonia X X X X X X
Finland X   X  
France X   X  
Germany X X X X X X
Greece      
Hungary X X X X X X
Ireland X   X  
Italy X   X X 
Latvia X X X X X X
Lithuania      
Luxembourg      
Malta    X X 
Poland      
Portugal    X X 
Netherlands X X X X X X
Norway      
Slovak Republic X X X X X X
Slovenia X X X X X X
Spain X   X  
Sweden X X X X  X
United Kingdom    X  
Source: www.unep.org/ozone/Information_for_the_Parties/3Bi_dec12-2-3.asp
Country Non-steroidal anti-inflammatories
Cromoglicic acid Nedrocromil    
Austria      
Belgium X X    
Cyprus      
Czech Republic X X    
Denmark X X    
Estonia X X    
Finland X X    
France X X    
Germany X X    
Greece X X    
Hungary      
Ireland      
Italy      
Latvia X X    
Lithuania      
Luxembourg      
Malta      
Poland      
Portugal X     
Netherlands X X    
Norway      
Slovak Republic X X    
Slovenia X X    
Spain  X    
Sweden      
United Kingdom      
Source: www.unep.org/ozone/Information_for_the_Parties/3Bi_dec12-2-3.asp
Country Anticholinergic Bronchodilators
Ipratropium bromide Oxitropium Bromide    
Austria      
Belgium X X    
Cyprus X X    
Czech Republic X X    
Denmark X X    
Estonia X X    
Finland X X    
France      
Germany X X    
Greece X X    
Hungary X X    
Ireland X X    
Italy      
Latvia      
Lithuania      
Luxembourg      
Malta X X    
Netherlands X X    
Poland      
Portugal X     
Norway      
Slovak Republic X X    
Slovenia      
Spain X X    
Sweden X X    
United Kingdom X X    
Source: www.unep.org/ozone/Information_for_the_Parties/3Bi_dec12-2-3.asp
Country Long-acting Beta Agonist Bronchodilators
Formoterol Salmeterol    
Austria      
Belgium      
Cyprus      
Czech Republic      
Denmark      
Estonia      
Finland      
France      
Germany X X    
Greece      
Hungary      
Ireland      
Italy X     
Latvia      
Lithuania      
Luxembourg      
Malta      
Netherlands      
Poland      
Portugal      
Norway      
Slovak Republic      
Slovenia      
Spain      
Sweden      
United Kingdom      
Source: www.unep.org/ozone/Information_for_the_Parties/3Bi_dec12-2-3.asp
Country Combinations of active ingredients in a single MDI
Austria      
Belgium      
Cyprus      
Czech Republic      
Denmark      
Estonia      
Finland      
France      
Germany X     
Greece      
Hungary      
Ireland      
Italy      
Latvia      
Lithuania      
Luxembourg      
Malta      
Netherlands      
Poland      
Portugal      
Norway      
Slovak Republic      
Slovenia      
Spain      
Sweden      
United Kingdom      
Source: www.unep.org/ozone/Information_for_the_Parties/3Bi_dec12-2-3.asp
ANNEX II

Quota of controlled substances of Group I that may be used in the production of metered dose inhalers (MDIs) for the treatment of asthma and other chronic obstructive pulmonary diseases (COPDs) are allocated to:

 3M Health Care (UK)
 Bespak (UK)
 Boehringer Ingelheim (DE) on behalf of Boehringer Ingelheim France
 Chiesi (IT)
 IVAX (IE)
 Lab Aldo-Union (ES)
 Sicor (IT)
 Valeas (IT)
 V.A.R.I. (IT)

ANNEX III

Quota of controlled substances of Group I and II that may be used for laboratory and analytical uses, are allocated to:

 Acros organics bvba (BE)
 Bie & Berntsen (DK)
 Biosolve (NL)
 Carlo Erba Reactifs-SDS (FR)
 CNRS — Groupe de Physique des Solides (FR)
 Honeywell Fluorine Products Europe (NL)
 Honeywell Specialty Chemicals (DE)
 Ineos Fluor (UK)
 Katholieke Universiteit Leuven (BE)
 LGC Promochem (DE)
 Mallinckrodt Baker (NL)
 Merck KGaA (DE)
 Mikro + Polo (SI)
 Panreac Química (ES)
 Sanolabor (SI)
 Sigma Aldrich Chimie (FR)
 Sigma Aldrich Company (UK)
 Sigma Aldrich Logistik (DE)
 Tazzetti Fluids (IT)
 University of Technology Vienna (AT)

ANNEX IV

Quota of controlled substances of Group III that may be used for laboratory and analytical uses are allocated to:

 Airbus France (FR)
 Ineos Fluor (UK)
 Ministry of Defense (NL)
 Sigma Aldrich Chimie (FR)

ANNEX V

Quota of controlled substances of Group IV that may be used for laboratory and analytical uses, are allocated to:

 Acros Organics (BE)
 Bie & Berntsen (DK)
 Biosolve (NL)
 Carlo Erba Reactifs-SDS (FR)
 Health Protection Inspectorate-Laboratories (EE)
 Institut Scientifique de Service Public (ISSeP) (BE)
 Katholieke Universiteit Leuven (BE)
 Mallinckrodt Baker (NL)
 Merck KGaA (DE)
 Mikro + Polo (SI)
 Panreac Química (ES)
 Sanolabor d.d. (SI)
 Sigma Aldrich Chimie (FR)
 Sigma Aldrich Company (UK)
 Sigma Aldrich Laborchemikalien (DE)
 Sigma Aldrich Logistik (DE)
 VWR I.S.A.S. (FR)
 YA-Kemia Oy (FI)

ANNEX VI

Quota of controlled substances of Group V that may be used for laboratory and analytical uses are allocated to:

 Acros Organics (BE)
 Bie & Berntsen (DK)
 Katholieke Universiteit Leuven (BE)
 Mallinckrodt Baker (NL)
 Merck KGaA (DE)
 Mikro + Polo (SI)
 Panreac Química (ES)
 Sanolabor d.d. (SI)
 Sigma Aldrich Chimie (FR)
 Sigma Aldrich Company (UK)
 Sigma Aldrich Logistik (DE)
 YA-Kemia Oy (FI)

ANNEX VII

Quota of controlled substances of Group VI that may be used for laboratory and analytical critical uses are allocated to:
Sigma-Aldrich Chemie GmbH (DE)

ANNEX VIII

Quota of controlled substances of Group VII that may be used for laboratory and analytical uses are allocated to:

 Ineos Fluor (UK)
 Katholieke Universiteit Leuven (BE)
 Sigma Aldrich Logistik (FR)
 Sigma Aldrich Company (UK)

ANNEX IX

Quota of controlled substances of Group IX that may be used for laboratory and analytical uses are allocated to:

 Ineos Fluor (UK)
 Katholieke Universiteit Leuven (BE)
 Sigma Aldrich Logistik (FR)
 YA-Kemia Oy (FI)

ANNEX X

[This Annex is not published because it contains confidential commercial information.]
